CN114533753A - 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 - Google Patents

含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 Download PDF

Info

Publication number
CN114533753A
CN114533753A CN202210024252.2A CN202210024252A CN114533753A CN 114533753 A CN114533753 A CN 114533753A CN 202210024252 A CN202210024252 A CN 202210024252A CN 114533753 A CN114533753 A CN 114533753A
Authority
CN
China
Prior art keywords
selenium
present application
subject
enriched yeast
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210024252.2A
Other languages
English (en)
Chinese (zh)
Inventor
R.鲍威尔
C.伊根
A.伊安尼库里斯
兰子鉴
肖日进
L.C.杰克逊
S.奎亚特科夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alltech Corp
Original Assignee
Alltech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Corp filed Critical Alltech Corp
Publication of CN114533753A publication Critical patent/CN114533753A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202210024252.2A 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 Pending CN114533753A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15
US61/788133 2013-03-15
PCT/US2014/029328 WO2014144776A1 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
CN201480028372.3A CN105377271A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480028372.3A Division CN105377271A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用

Publications (1)

Publication Number Publication Date
CN114533753A true CN114533753A (zh) 2022-05-27

Family

ID=51537786

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210024252.2A Pending CN114533753A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
CN202210387608.9A Pending CN114984038A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
CN201480028372.3A Pending CN105377271A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210387608.9A Pending CN114984038A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
CN201480028372.3A Pending CN105377271A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用

Country Status (15)

Country Link
US (1) US9833486B2 (enExample)
EP (1) EP2968404A4 (enExample)
JP (1) JP6313418B2 (enExample)
KR (1) KR102245702B1 (enExample)
CN (3) CN114533753A (enExample)
AU (1) AU2014228785B2 (enExample)
BR (1) BR112015022514A2 (enExample)
CA (1) CA2903845C (enExample)
CL (1) CL2015002677A1 (enExample)
HK (1) HK1216506A1 (enExample)
MX (1) MX359626B (enExample)
RU (1) RU2663127C2 (enExample)
SG (2) SG11201507061XA (enExample)
WO (1) WO2014144776A1 (enExample)
ZA (1) ZA201506759B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114931569A (zh) * 2022-06-22 2022-08-23 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302A (zh) * 2023-03-31 2023-06-27 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618A (zh) * 2023-06-15 2023-07-14 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022936A2 (pt) 2013-03-14 2017-07-18 J Schentag Jerome vesículas de colestossoma para a incorporação de moléculas em quilomícrons
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017160678A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
AU2019261476B2 (en) * 2018-04-25 2021-11-18 Oncocross Co.,Ltd. Composition for preventing and treating muscular disease
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN109820933A (zh) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 减肥片及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
KR20230029674A (ko) * 2020-06-29 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 생물반응기로부터의 샘플을 분석하기 위한 자동화 시스템 및 방법
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114924001B (zh) * 2022-05-12 2024-11-19 中国计量科学研究院 一种基于独立校准的含磷或含硒化合物标准溶液定值方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
EP1774972A1 (en) * 2005-10-14 2007-04-18 Alltech, Inc. Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes
US20080008692A1 (en) * 2005-10-14 2008-01-10 Alltech, Inc. Methods and compositions for altering cell function

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
EP1643865A1 (en) * 2003-06-04 2006-04-12 Willem Jacob Serfontein Nutritional compositions and use thereof
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20100247679A1 (en) 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
US8846111B2 (en) * 2007-05-18 2014-09-30 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
CN102056499B (zh) * 2007-10-16 2014-12-31 阿克特基因组学有限公司 用于调节脂质代谢的组合物
CN101579355B (zh) * 2009-05-27 2010-12-08 徐建兴 一种维护线粒体功能的营养组合物及其应用
RU2012120785A (ru) * 2009-10-22 2013-11-27 ПРОПАНК ПиТиУай ЛТД Фармацевтические композиции
JP5896421B2 (ja) * 2010-04-22 2016-03-30 国立大学法人京都大学 多能性幹細胞から骨格筋または骨格筋前駆細胞への分化誘導法
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물
WO2012141316A1 (ja) * 2011-04-13 2012-10-18 味の素株式会社 栄養組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
EP1774972A1 (en) * 2005-10-14 2007-04-18 Alltech, Inc. Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes
CN101073584A (zh) * 2005-10-14 2007-11-21 全面技术公司 改变细胞功能的方法和组合物
US20080008692A1 (en) * 2005-10-14 2008-01-10 Alltech, Inc. Methods and compositions for altering cell function

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114931569A (zh) * 2022-06-22 2022-08-23 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302A (zh) * 2023-03-31 2023-06-27 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618A (zh) * 2023-06-15 2023-07-14 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Also Published As

Publication number Publication date
CA2903845A1 (en) 2014-09-18
JP6313418B2 (ja) 2018-04-18
SG11201507061XA (en) 2015-10-29
JP2016516058A (ja) 2016-06-02
AU2014228785B2 (en) 2018-01-25
KR20150132374A (ko) 2015-11-25
NZ711842A (en) 2021-04-30
US20160113977A1 (en) 2016-04-28
RU2015139742A (ru) 2017-04-21
AU2014228785A1 (en) 2015-09-24
US9833486B2 (en) 2017-12-05
CN114984038A (zh) 2022-09-02
MX2015013275A (es) 2015-12-11
CL2015002677A1 (es) 2016-12-09
CA2903845C (en) 2022-08-23
CN105377271A (zh) 2016-03-02
EP2968404A1 (en) 2016-01-20
HK1216506A1 (zh) 2016-11-18
KR102245702B1 (ko) 2021-04-28
MX359626B (es) 2018-10-01
ZA201506759B (en) 2017-03-29
EP2968404A4 (en) 2017-01-04
BR112015022514A2 (pt) 2017-07-18
SG10202101918RA (en) 2021-03-30
WO2014144776A1 (en) 2014-09-18
RU2663127C2 (ru) 2018-08-01

Similar Documents

Publication Publication Date Title
AU2014228785B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Wang et al. Tryptophan-rich diet ameliorates chronic unpredictable mild stress induced depression-and anxiety-like behavior in mice: The potential involvement of gut-brain axis
Liu et al. The physiological metabolite α-ketoglutarate ameliorates osteoarthritis by regulating mitophagy and oxidative stress
JP6081195B2 (ja) エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する腫瘍性障害の診断のための方法
Sun et al. Berberine inhibits breast carcinoma proliferation and metastasis under hypoxic microenvironment involving gut microbiota and endogenous metabolites
Yang et al. Favourable effects of grape seed extract on intestinal epithelial differentiation and barrier function in IL10-deficient mice
Wang et al. Nitration-mediated deficiency of cystathionine β-synthase activity accelerates the progression of hyperhomocysteinemia
Yu et al. Mechanisms of epigallocatechin gallate (EGCG) in ameliorating hyperuricemia: insights into gut microbiota and intestinal function in a mouse model
Gong et al. Integration of transcriptomics and metabonomics revealed the protective effects of hemp seed oil against methionine–choline-deficient diet-induced non-alcoholic steatohepatitis in mice
Dang et al. Zishen Yutai pills restore fertility in premature ovarian failure through regulating arachidonic acid metabolism and the ATK pathway
Xu et al. Metformin-mediated intestinal AMPK activation ameliorates PCOS through gut microbiota modulation and metabolic pathways
Ren et al. Astaxanthin slows down skeletal muscle atrophy in H22 tumor-bearing mice during sorafenib treatment by modulating the gut microbiota
Li et al. The prebiotics 2′-fucosyllactose prevent high-fat diet induced obesity via the promotion of thermogenesis and modulation of gut microbiota
Tu et al. Dietary administration of black raspberries modulates arsenic biotransformation and reduces urinary 8-oxo-2′-deoxyguanosine in mice
EP3142660B1 (en) Composition comprising 7-hydroxymatairesinol
Gu et al. β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice
Wang et al. Integrated proteomics and metabolomics to clarify the essential beneficial mechanisms of L-theanine in alleviating ISO-induced cardiac damage in mice
NZ711842B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Sun et al. Effects of Polyphenols and Ascorbic Acid in Honey From Diverse Floral Origins on Liver Alcohol Metabolism
WO2025232059A1 (en) A beneficial bacterium for colorectal cancer prevention and inhibition of pathogenic bacteria
Spada Glutamine deprivation and glutaminase 1 inhibitory effect in colorectal cancer cells: a metabolomic study
Ahn et al. Unacylated Ghrelin Counteracts Contractile and Mitochondrial Dysfunction in Cancer Cachexia
Chen et al. Dietary hispidulin ameliorated chemically-induced colitis by inhibiting epithelial cell ferroptosis via the ACAT2-GPX4 axis and remodeling the gut microbiota
Li et al. The cinnamaldehyde-thiosemicarbazone-zinc (II) complex induces apoptosis in CAL-27 cells
CN117547574A (zh) 黄连解毒丸在干预实热上火证候中的应用及检测方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220527